• 1973

    Discovery of Rotavirus

    In 1973, Rotavirus was firstly discovered by Prof. Ruth Bishop from the University of Melbourne, Australia

  • 1976

    Collaboration between Indonesia and Australia

    In 1976, Prof.dr. Yati Soenarto, Ph.D., Sp.A(K) initiated research collaboration in diarrheal disease and global child health between Universitas Gadjah Mada (Indonesia) and the University of Melbourne (Australia).

    1976

  • 1977

    Surveillance: Causes of Diarrhea

    Started from 1977, diarrheal surveillance and studies conducted by UGM team and the University of Melbourne team identified that Rotavirus is the main cause of childhood diarrhea in Yogyakarta.

  • 1997

    Asian Rotavirus Surveillance Network (ARSN)

    In 1997, Asian Rotavirus Surveillance Network (ARSN) was established to study the burden of diarrheal disease in Asia countries.

    1997

  • 1998

    World-First Rotavirus Vaccine

    In 1998, the world-first rotavirus vaccine, RotaShield ® was released. The manufacturer of the vaccine, however, withdrew it from the market in 1999.

  • 2000

    Indonesian Rotavirus Surveillance Network (IRSN)

    In 2000, Indonesian Rotavirus Surveillance Network (IRSN) was established and headquartered in Center for Child Health (formerly named Pediatric Research Office) UGM. IRSN was supported by WHO-SEARO. The IRSN was conducted in several teaching hospitals and regional hospitals to identify the causes and burden of diarrheal disease.

    2000

  • 2006

    Commercial Rotavirus Vaccine

    Commercial Rotavirus vaccines have been available: Rotateq ® in 2006 and Rotarix ® in 2008.

  • 2009

    WHO Position Paper: Rotavirus Vaccines

    In 2009 & 2013, WHO recommended: “Rotavirus vaccines should be included in all national immunization programmes and considered a priority, particularly in countries with high RVGE-associated fatality rates, such as in south and south-eastern Asia and sub-Saharan Africa.”

    2009

  • 2013

    Rotavirus Vaccine Phase IIb Clinical Trial

    Rotavirus RV3-BB Vaccine (MCRI) Phase IIb Clinical Trial was conducted with 1649 babies in Sleman (Yogyakarta) and Klaten (Central Java) between 2013-2016. The trial was a collaboration between CCH-PRO, Murdoch Children’s Research Institute (MCRI), and PT Bio Farma while funded by National Health and Medical Research Council (NHMRC), Bill and Melinda Gates Foundation (BMGF), andPT Bio Farma. The trial result can be found in the New England Journal Medicine in 2018.​

  • 2017

    Rotavirus Vaccine Phase I Clinical Trial

    Rotavirus RV3 (Bio Farma) Vaccine phase I clinical trial was conducted in Klaten, Central Java. This trial was funded by PT Bio Farma, the state-owned vaccine manufacturer. The technology transfer from MCRI to PT Bio Farma was done to support the introduction of Rotavirus Vaccine into National Immunization Program in Indonesia.

    2017

  • 2020

    Rotavirus Vaccine Phase III Clinical Trial

    Rotavirus RV3 (Bio Farma) Vaccine Phase III Clinical Trial is being conducted in Klaten and Surakarta, Central Java, from 2020. The trial was conducted by Center for Child Health (CCH-PRO) UGM and Pediatric Research Center UNS based on the vaccine’s safety profile from the previous phase I trial. This is the last phase before the vaccine being licensed and introduced into the National Immunization Program and post-marketing surveillance.